Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Carcinoma|Stage IV Breast Cancer AJCC v6 and v7
Interventions: DRUG: Fulvestrant|OTHER: Laboratory Biomarker Analysis|DRUG: Letrozole|DRUG: Palbociclib|BIOLOGICAL: Pembrolizumab
Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)